Children's migraine attacks cut 56% by topiramate plus vitamin D – ranked 2nd of 22 preventives - meta-analysis
Preventive Medications in Pediatric Migraine: A Network Meta-Analysis
JAMA Network Open, October 10, 2024, https://doi.org/10.1001/jamanetworkopen.2024.38666
Omid Kohandel Gargari, Sepehr Aghajanian, Mansoureh Togha, Fateme Mohammadifard, Romina Abyaneh, Sheida Mobader Sani, Reza Samiee, Ali Kermanpour, Niloofar Seighali, Faraidoon Haghdoost
Summary by Claude Opus 5.5 - November, 2026
Topiramate plus vitamin D3 ranked second of 22 treatments for cutting migraine attacks in children — but that ranking rests on just two small trials.
This network meta-analysis pooled 45 randomized trials with 3,771 children and teens. Compared with placebo, topiramate plus vitamin D3 cut monthly attacks by 56% (ratio of means 0.44; 95% CI 0.30–0.65), second only to pregabalin (0.38). Topiramate alone cut attacks by 30% (0.70). Dividing the two (0.44 ÷ 0.70 ≈ 0.63) suggests that adding vitamin D left roughly a third fewer attacks than topiramate alone. Riboflavin (vitamin B2) alone also did well (0.50).
The vitamin D evidence comes from two trials of topiramate with vs. without D3 (details below are from the trial papers, not this one):
- Fallah 2020 — 57 children, weekly D3 printed as 500,000 IU (possibly a misprint for 50,000), 2 months, open-label, no placebo
- Kotb Elmala 2022 — 56 children, 5,000 IU D3 daily, 4 months, double-blind with placebo
Neither trial gave a loading dose, and this paper reports no 25(OH)D levels.
For topiramate plus D3, the other outcomes — share of children whose attacks were cut by half (RR 1.59; 0.96–2.63), pain intensity, attack length and disability — were not statistically significant. No drug improved quality of life or attack duration.
The widely reported "88% fewer headaches" for pregabalin plus vitamin D3 and riboflavin is a statistical projection that assumes the effects simply add up; no child in any trial took that combination. The authors note "the actual figures may be lower in clinical scenarios."
What this does NOT show / limitations
- No trial compared topiramate + D3 with plain placebo; the 56% figure is indirect, routed through topiramate trials
- About 113 children in two trials carry the vitamin D result; no trial in the network tested vitamin D alone
- Fallah's children were not vitamin D deficient at the start; deficient children may respond differently
- The Fallah trial lasted only 2 months with no loading dose. Vitamin D typically needs about 3 months to reach a new steady blood level, so any benefit may be understated. The meta-analysis did not analyze results by trial length or vitamin D dose.
- High heterogeneity (I² 68%), mostly small trials, about 42–45% of participants from Iran, and a large placebo effect in children
Related in VitaminDWiki
- Children's migraines cut further by adding weekly vitamin D to topiramate (500,000 IU ?) - RCT
- Migraine in children reduced with vitamin D supplementation – April 2014
- Migraines in youths with low Vitamin D wonderfully treated by Vitamin D
- Half as many headaches if high Vitamin D level (age 6-19)
- Migraine headaches reduced with 50,000 IU vitamin D weekly - RCT
- Headaches helped by Vitamin D in 7 studies
- Magnesium and Migraines - many studies
- Cluster and Migraine headache treatment protocol
- Vitamin D and Migraine
- Migraine and Vitamin D
- Headache